Pharmacogenomics in prevention of diabetic cardiovascular disease: Utilization of the haptoglobin genotype in determining benefit from vitamin E

Expert Review of Cardiovascular Therapy

Volumn 5, Issue 6, 2007, Pages 1105-1111

  Levy, Andrew P ^a   Blum, Shany ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Antioxidant vitamins; Cardiovascular disease; Diabetes oxidative stress pharmacogenomics

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; DEFEROXAMINE; GLYCOPROTEIN; HAPTOGLOBIN; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN; HYDROGEN PEROXIDE; LOW DENSITY LIPOPROTEIN; PLACEBO; RAMIPRIL; REACTIVE OXYGEN METABOLITE; SUPEROXIDE; SUPEROXIDE DISMUTASE; UBIQUINONE;

ANTIOXIDANT ACTIVITY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DEATH; DIABETES MELLITUS; EVIDENCE BASED MEDICINE; GENE LOCUS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HEART INFARCTION; HEART PROTECTION; HOMOZYGOSITY; HUMAN; INDIVIDUALIZATION; LIPID OXIDATION; MARKER GENE; MONOTHERAPY; MORTALITY; NONHUMAN; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PATIENT CARE; PHARMACOGENOMICS; REVIEW; TREATMENT OUTCOME; VITAMIN SUPPLEMENTATION;

ANTIOXIDANTS; CARDIOVASCULAR DISEASES; DIABETIC ANGIOPATHIES; FEMALE; HAPTOGLOBINS; HUMANS; MALE; OXIDATIVE STRESS; PHARMACOGENETICS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TREATMENT OUTCOME; VITAMIN E;

EID: 37349131252     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.5.6.1105     Document Type: Review

References (45)

1. Witztum JL. The oxidation hypothesis of atherosclerosis. Lancet 344, 793-795 (1994).
2. Singh U, Devaraj S, Jialal I. Vitamin E, oxidative stress and inflammation. Ann. Rev. Nutr. 25, 151-174 (2005).
3. Johansen JS, Harris A, Rychly D, Ergul A. Oxidative stress and the use of antioxidants in diabetes: linking basic science to clinical practice. Card. Diab. 4, 5-15 (2005).
4. Lee DH, Folsom AR, Harnack L, Halliwell B, Jacobs DR. Common presence of non-transferrin bound iron among patients with Type II diabetes. Diab. Care 29, 1090-1095 (2006).
5. Ceriello PA. Oxidative stress and diabetes associated complications. Endo. Prac. 12, 60-62 (2006).
6. Wang X, Quinn PJ. Vitamin E and its function in membranes. Prog. Lipid Res. 38, 309-316 (1999).
7. Vivekananthan DP, Penn MS, Sapp SK, Hsu A, Topol EJ. Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomized trials. Lancet 361, 2017-2023 (2003).
8. Renard C, Van Obberghen E. Role of diabetes in atherosclerosis pathogenesis. What have we learned from animal models? Diab. Metab. 32, 15-29 (2006).
9. Otero P, Bonet B, Herrera E, Rabano A. Development of atherosclerosis in the diabetic BALB/c mice. Prevention with vitamin E administration. Atherosclerosis 182, 259-265 (2005).
10. Gaziano JM. Vitamin E and cardiovascular disease: observational studies. Ann. NY Acad. Sci. 1031, 280-291 (2004).
11. Forman D, Altman D. Vitamins to prevent cancer: supplementary problems. Lancet 364, 1193-1194 (2004).
12. Miller ER, Barriuso RP, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high dosage vitamin E supplementation may increase all cause mortality. Ann. Intern. Med. 142, 37-46 (2005).
13. HOPE and HOPE-2 Trial Investigators. Effects of long-term vitamin E supplementation on cardiovascular events and cancer. JAMA 293, 1338-1347 (2005).
14. Brown BG, Crowley J. Is there any hope for vitamin E? JAMA 293, 1387-1390 (2005).
15. Steinberg D, Witztum JL. Is the oxidative modification hypothesis relevant to human atherosclerosis? Do the antioxidant trials conducted to date refute the hypothesis? Circulation 105, 2107-2111 (2002).
16. Lee IM, Cook NR, Gaziano JM et al. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Womens Health Study: a randomized controlled trial. JAMA 294, 56-65 (2005).
17. Brown BG, Zhao XQ, Chait A et al. Simvastatin and niacin, antioxidant vitamins or the combination for the prevention of coronary disease. N. Engl. J. Med. 345, 1583-1592 (2001).
18. HOPE Trial Investigators. Vitamin E supplementation and cardiovascular events in high risk patients. N. Engl. J. Med. 342, 154-161 (2000).
19. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high risk individuals; a randomized placebo controlled trial. Lancet 360, 7-22 (2002).
20. Boaz M, Smetana S, Weinstein T et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomized placebo controlled trial. Lancet 356, 1213-1218 (2000).
21. Simon R, Wang SJ. Use of genomic signatures in therapeutics development in oncology and other diseases. Pharmacogenomics 6, 166-173 (2006).
22. Bowman BH, Kurosky A. Haptoglobin: the evolutionary product of duplication, unequal crossing over, and point mutation. Adv. Hum. Genet. 12, 189-261 (1982).
23. Levy AP, Hochberg I, Jablonski K et al. Haptoglobin phenotype and the risk of cardiovascular disease in individuals with diabetes: the Strong Heart Study. J. Am. Coll. Card. 40, 1984-1990 (2002).
24. Roguin A, Koch W, Kastrati A, Aronson D, Schomig A, Levy AP. Haptoglobin genotype is predictive of major adverse cardiac events in the one year period after PTCA in individuals with diabetes. Diab. Care 26, 2628-2631 (2003).
25. Suleiman M, Aronson D, Asleh R et al. Haptoglobin polymorphism predicts 30-day mortality and heart failure in patients with diabetes and acute myocardial infarction. Diabetes 19, 2802-2806 (2005).
26. Levy AP, Levy JE, Kalet-Litman S et al. Haptoglobin genotype is a determinant of iron, lipid peroxidation and macrophage accumulation in the atherosclerotic plaque. Arterioscl. Thromb Vasc. Biol. 27, 1419-1425 (2007).
27. Miller-Lotan R, Miller B, Aronson D, Asaf R, Nakhoul F, Levy AP. Retinal capillary basement membrane thickness in diabetic mice genetically modified at the haptoglobin locus. Diab. Met. Res. Rev. 23, 152-156 (2007).
28. Miller-Lotan R, Herskowitz Y, Kalet-Litman S et al. Increased renal hypertrophy in diabetic mice genetically modified at the haptoglobin locus. Diab. Met. Res. Rev. 21, 332-337 (2005).
29. Blum S, Asaf R, Guetta J et al. Haptoglobin genotype determines myocardial infarct size in diabetic mice. J. Am. Coll. Card. 49, 82-87 (2007).
30. Asleh R, Miller-Lotan R, Aviram M et al. Haptoglobin genotype is a regulator of reverse cholesterol transport in diabetes in vitro and in vivo. Circ. Res. 99, 1419-1425 (2006).
31. Sadrzadeh SMH, Graf E, Panter SS et al. Hemoglobin - a biologic Fenton reagent. J. Biol. Chem. 259, 14354-14356 (1984).
32. Frank M, Lache O, Enav B et al. Structure/function analysis of the anti-oxidant properties of haptoglobin. Blood 98, 3693-3698 (2001).
33. Miller YI, Altamentova SM, Shaklai N. Oxidation of low density lipoprotein by hemoglobin stems from a heme initiated globin radical: antioxidant role of haptoglobin. Biochemistry 36, 12189-12198 (1997).
34. Hershko C. The fate of circulating hemoglobin. Br. J. Hematol. 29, 199 (1975).
35. Kristiansen M, Graversen JH, Jacobsen C et al. Identification of the hemoglobin scavenger receptor. Nature 409, 198-201 (2001).
36. Graversen JH, Madsen M, Moestrup SK. CD163: a signal receptor scavenging haptoglobin hemoglobin complexes from plasma. Int. J. Biochem. Cell Biol. 234, 309-314 (2002).
37. Levy AP, Moreno PR. Intraplaque hemorrhage. Curr. Mol. Med. 6, 479-488 (2006).
38. Asleh R, Guetta J, Kalet-Litman S, Miller-Lotan R, Levy AP. Haptoglobin genotype and diabetes dependent differences in iron mediated oxidative stress in vitro and in vivo. Circ. Res. 96, 435-441 (2005).
39. Rich RL, Myszka DG. Advances in surface plasmon resonance biosensor analysis. Curr. Opin. Biotech. 11, 54-61 (2000).
40. Bamm VV, Tsemakhovich VA, Shaklai M, Shaklai N. Haptoglobin phenotypes differ in their ability to inhibit heme transfer from hemoglobin to LDL. Biochemistry 43, 3899-3906 (2004).
41. Asleh R, Marsh S, Shiltruck M et al. Genetically determined heterogeneity in hemoglobin scavenging and susceptibility to diabetic cardiovascular disease. Circ. Res. 92, 1193-1200 (2003).
42. Moreno PR, Purushothaman KR, Sirol M, Levy AP, Fuster V. Neovascularization in human atherosclerosis. Circulation 113, 2245-2252 (2006).
43. Esposito K, Nappo F, Marfella R et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans. Role of oxidative stress. Circulation 106, 2067-2072 (2002).
44. Shanmugam N, Reddy MA, Guha M, Natarajan R. High glucose induced expression of proinflammatory cytokine and chemokine genes in monocytic cells. Diabetes 52, 1256-1264 (2003).
45. Levy AP, Gerstein HC, Miller-Lotan R et al. The effect of vitamin E supplementation on cardiovascular risk in diabetic individuals with different haptoglobin phenotypes. Diab. Care 27, 2767 (2004).